title: Haemolytic uremic syndrome and gemcitabine: jaundice is not always progression in cholangiocarcinoma.
authors.forename: Laurence
authors.initials: L
authors.lastname: Crouzet
authors.forename: Julien
authors.initials: J
authors.lastname: Edeline
authors.forename: Fanny
authors.initials: F
authors.lastname: Le Du
authors.forename: Eveline
authors.initials: E
authors.lastname: Boucher
authors.forename: Odile
authors.initials: O
authors.lastname: Audrain
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Raoul
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D001650:Bile Duct Neoplasms / Q000188:drug therapy*; D001653:Bile Ducts, Intrahepatic / Q000187:drug effects*; D018281:Cholangiocarcinoma / Q000188:drug therapy*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D018450:Disease Progression; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced* / Q000628:therapy; D006801:Humans; D007565:Jaundice / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine